It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Nanophthalmos is a rare condition defined by a small, structurally normal eye with resultant high hyperopia. While six genes have been implicated in this hereditary condition (MFRP, PRSS56, MYRF, TMEM98, CRB1,VMD2/BEST1), the relative contribution of these to nanophthalmos or to less severe high hyperopia (≥ + 5.50 spherical equivalent) has not been fully elucidated. We collected probands and families (n = 56) with high hyperopia or nanophthalmos (≤ 21.0 mm axial length). Of 53 families that passed quality control, plausible genetic diagnoses were identified in 10/53 (18.8%) by high-throughput panel or pooled exome sequencing. These include 1 TMEM98 family (1.9%), 5 MFRP families (9.4%), and 4 PRSS56 families (7.5%), with 4 additional families having single allelic hits in MFRP or PRSS56 (7.5%). A novel deleterious TMEM98 variant (NM_015544.3, c.602G>C, p.(Arg201Pro)) segregated with disease in 4 affected members of a family. Multiple novel missense and frameshift variants in MFRP and PRSS56 were identified. PRSS56 families were more likely to have choroidal folds than other solved families, while MFRP families were more likely to have retinal degeneration. Together, this study defines the prevalence of nanophthalmos gene variants in high hyperopia and nanophthalmos and indicates that a large fraction of cases remain outside of single gene coding sequences.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Department of Human Genetics, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
2 National Eye Institute, National Institutes of Health, Ophthalmic Genetics and Visual Function Branch, Bethesda, USA (GRID:grid.280030.9) (ISNI:0000 0001 2150 6316)
3 University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
4 University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); National Eye Institute, National Institutes of Health, Ophthalmic Genetics and Visual Function Branch, Bethesda, USA (GRID:grid.280030.9) (ISNI:0000 0001 2150 6316); Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847)
5 University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); The Ohio State University, Department of Ophthalmology and Visual Sciences, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)